Laboratorios Farmaceuticos Rovi (ES:ROVI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laboratorios Farmacéuticos ROVI has successfully passed all proposed resolutions during its Ordinary General Shareholders’ Meeting, including the approval of annual accounts, management reports, a dividend payout, and the re-election of board members and auditors for the upcoming year. Shareholders endorsed a dividend distribution equivalent to 35% of the 2023 consolidated profit, and confirmed KPMG Auditores, S.L. as the company’s auditors for 2024. The company will also implement a Long-Term Incentive Plan and a share capital reduction by amortizing its own shares.
For further insights into ES:ROVI stock, check out TipRanks’ Stock Analysis page.